Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC876 in relapsed or refractory aggressive non-Hodgkin lymphoma
ChiCTR1800019661Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- Oct 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 1 more, sponsored by Ruijin Hospital. Primary endpoints: Incidence of dose-limiting toxicity and Overall response rate. Started Oct 2018; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on ChiCTR1800019661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019661.